Clinical and Experimental Pharmacology and Physiology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Valproic acid reduces muscle susceptibility to contraction-induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy
Clin Exp Pharmacol Physiol. 2023 Jun 29. doi: 10.1111/1440-1681.13804. Online ahead of print.ABSTRACTSkeletal muscles in animal models of Duchenne muscular dystrophy (DMD) are more susceptible to contraction-induced functional loss, which is not related to fatigue. Valproic acid (VPA) reportedly improves serological and histological markers of damage in dystrophin-deficient murine muscle. Here, we tested whether VPA would reduce the susceptibility to contraction-induced functional loss in two murine DMD models. Adult female mdx (mild) and D2-mdx (severe) DMD murine models were administered VPA (240 mg/kg) or saline for 7 d...
Source: Clinical and Experimental Pharmacology and Physiology - June 29, 2023 Category: Drugs & Pharmacology Authors: Dylan Moutachi M égane Lemaitre Cl ément Delacroix Onnik Agbulut Denis Furling Arnaud Ferry Source Type: research

Valproic acid reduces muscle susceptibility to contraction-induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy
Clin Exp Pharmacol Physiol. 2023 Jun 29. doi: 10.1111/1440-1681.13804. Online ahead of print.ABSTRACTSkeletal muscles in animal models of Duchenne muscular dystrophy (DMD) are more susceptible to contraction-induced functional loss, which is not related to fatigue. Valproic acid (VPA) reportedly improves serological and histological markers of damage in dystrophin-deficient murine muscle. Here, we tested whether VPA would reduce the susceptibility to contraction-induced functional loss in two murine DMD models. Adult female mdx (mild) and D2-mdx (severe) DMD murine models were administered VPA (240 mg/kg) or saline for 7 d...
Source: Clinical and Experimental Pharmacology and Physiology - June 29, 2023 Category: Drugs & Pharmacology Authors: Dylan Moutachi M égane Lemaitre Cl ément Delacroix Onnik Agbulut Denis Furling Arnaud Ferry Source Type: research

Valproic acid reduces muscle susceptibility to contraction-induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy
Clin Exp Pharmacol Physiol. 2023 Jun 29. doi: 10.1111/1440-1681.13804. Online ahead of print.ABSTRACTSkeletal muscles in animal models of Duchenne muscular dystrophy (DMD) are more susceptible to contraction-induced functional loss, which is not related to fatigue. Valproic acid (VPA) reportedly improves serological and histological markers of damage in dystrophin-deficient murine muscle. Here, we tested whether VPA would reduce the susceptibility to contraction-induced functional loss in two murine DMD models. Adult female mdx (mild) and D2-mdx (severe) DMD murine models were administered VPA (240 mg/kg) or saline for 7 d...
Source: Clinical and Experimental Pharmacology and Physiology - June 29, 2023 Category: Drugs & Pharmacology Authors: Dylan Moutachi M égane Lemaitre Cl ément Delacroix Onnik Agbulut Denis Furling Arnaud Ferry Source Type: research

3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease
Clin Exp Pharmacol Physiol. 2023 Jun 18. doi: 10.1111/1440-1681.13799. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, for which no disease-modifying treatments are available yet. Thus, developing new neuroprotective drugs with the potential to delay or stop the natural course of the disease is necessary. The aim of the present study was to evaluate the neuroprotective effects of a newly synthesized 3-aminohydantoin derivative named 3-amino-5-benzylimidazolidine-2,4-dione (PHAH). The possible neuropro...
Source: Clinical and Experimental Pharmacology and Physiology - June 18, 2023 Category: Drugs & Pharmacology Authors: Sahar Mani Houda Bouchnak Sol ène Pradeloux Jamil Kraiem Denis Soulet Imed Messaoudi Source Type: research

3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease
Clin Exp Pharmacol Physiol. 2023 Jun 18. doi: 10.1111/1440-1681.13799. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, for which no disease-modifying treatments are available yet. Thus, developing new neuroprotective drugs with the potential to delay or stop the natural course of the disease is necessary. The aim of the present study was to evaluate the neuroprotective effects of a newly synthesized 3-aminohydantoin derivative named 3-amino-5-benzylimidazolidine-2,4-dione (PHAH). The possible neuropro...
Source: Clinical and Experimental Pharmacology and Physiology - June 18, 2023 Category: Drugs & Pharmacology Authors: Sahar Mani Houda Bouchnak Sol ène Pradeloux Jamil Kraiem Denis Soulet Imed Messaoudi Source Type: research